Information Provided By: 
Fly News Breaks for September 21, 2016
TSRO, CLVS, LLY
Sep 21, 2016 | 08:00 EDT
In the wake of recent speculation that Eli Lilly (LLY) has expressed interest in acquiring Clovis (CLVS), Leerink analyst Seamus Fernandez says the addition of a PARP inhibitor makes strategic sense, fitting in "extremely well" with the former's oncology portfolio. Further, the analyst believes that the "impressive" emerging data from the PARP inhibitor class is likely to place both TESARO (TSRO) and Clovis high on the list of potential M&A targets. Fernandez reiterates an Outperform rating on Eli Lilly's shares.
News For LLY;CLVS;TSRO From the Last 2 Days
There are no results for your query LLY;CLVS;TSRO
